Shaunee Health Care, an organization that is part of the US National Institutes of Health, recently released a statement announcing that it will begin testing its “cough booster” vaccine in 2020.

Shaunee Health says it will be testing its new “Cough Booster” vaccine, and the US Food and Drug Administration (FDA) will be involved in that testing.

The company says it expects the testing to begin in 2019.

Shawnee Health is part-owned by Pfizer.

In an email, the company’s CEO, Michael J. Johnson, said, “We have a long history of supporting research into the use of vaccines and diagnostics to improve health and save lives.” 

The announcement came on the heels of another announcement from the company that it has secured the necessary approval from the National Institutes for Health to begin testing their “couch pill” for the first time.

In a blog post, the FDA said that it is “aware of information about a new drug candidate that is being developed that may be effective in the prevention and treatment of acute myalgic encephalomyelitis (AME), the leading cause of chronic neurological and psychiatric illness.”

In addition to the cough booster vaccine, Shaunee also plans to test a “cognitive enhancer” that is designed to improve memory and focus.

The study will be conducted by researchers at the University of Wisconsin-Madison and University of Texas Southwestern Medical Center.